Roche Taps Atavistik Allosteric Platform
Roche agreed to pay Atavistik Bio $70 million upfront for a multi-target research collaboration using Atavistik’s AMPS platform to discover allosteric small molecules in cardiovascular, renal and metabolic disease. Atavistik may receive up to…
